KUALA LUMPUR April, 2026 — Aspirin, one of the world’s most widely used medications, is gaining renewed attention in the medical community following emerging evidence of its potential to reduce cancer recurrence and improve patient outcomes.
Recent clinical studies and ongoing research suggest that low-dose aspirin could play a role in cancer treatment strategies, particularly for certain high-risk patient groups. However, experts caution that broader use remains controversial due to safety concerns and incomplete evidence.
A major clinical trial led by researchers at Karolinska University Hospital studied nearly 4,000 patients who had undergone surgery for colorectal cancer.
The findings revealed that:
- Patients who took aspirin experienced less than half the recurrence risk compared to those receiving a placebo
- The study used a dosage of around 160 mg daily over three years
- Results were published in a leading medical journal, strengthening the credibility of the findings
Based on this evidence, Sweden is set to recommend low-dose aspirin therapy for selected patient groups starting in 2026.
Follow-up studies suggest that similar benefits may be achieved with lower doses of 75–100 mg, which are already commonly used for cardiovascular disease prevention.
This lower dosage is significant because it:
- Reduces the risk of serious side effects
- Maintains potential anti-cancer benefits
- Improves long-term treatment feasibility
Researchers emphasize that balancing effectiveness and safety will be key to future medical guidelines.
Scientists are increasingly understanding how aspirin works at the molecular level.
Key mechanisms include:
- Inhibiting the enzyme COX-2, which is linked to inflammation and abnormal cell growth
- Reducing platelet activity, helping immune cells better detect and attack cancer cells
- Enhancing the body’s natural immune response against tumors
A study from the University of Cambridge also found that aspirin may help immune cells recognize cancer more effectively, although this has so far been confirmed mainly in animal models.
Despite promising results, experts stress that aspirin is not a universal cancer treatment.
Key limitations include:
- Benefits appear strongest in specific genetic subtypes of cancer
- Evidence for other cancers—such as breast and prostate—is still under investigation
- Large-scale clinical trials are ongoing
Researchers warn that applying aspirin broadly without clear guidelines could lead to unintended risks.
One of the biggest challenges in expanding aspirin use is its potential side effects, which include:
- Gastrointestinal bleeding
- Stomach ulcers
- Internal bleeding
- Increased risk of hemorrhagic stroke
Medical experts emphasize that aspirin therapy should only be used under professional supervision, particularly for long-term use.
The scientific community remains divided on how widely aspirin should be recommended.
Some researchers argue that:
- Expanding aspirin use to people over 50 could reduce overall mortality rates
Others caution that:
- Preventive use in healthy individuals is fundamentally different from treatment in cancer patients
- More evidence is needed before making population-wide recommendations
Most experts agree that aspirin should currently be limited to specific high-risk groups until further research is completed.
Ongoing international studies are exploring aspirin’s role in:
- Breast cancer
- Gastrointestinal cancers
- Prostate cancer
If future trials confirm its effectiveness, aspirin could become a low-cost, widely accessible tool in cancer prevention and treatment.
However, scientists stress that more evidence is needed before it can be adopted as a standard therapy.
Aspirin’s emerging role in cancer prevention represents a potentially groundbreaking development in modern medicine.
While early findings are promising—particularly in reducing cancer recurrence—experts emphasize caution due to safety risks and limited evidence across different cancer types.
As research continues, aspirin could evolve from a common pain reliever into a powerful tool in the global fight against cancer—but only with careful, evidence-based application.
